D

Dongkook Pharmaceutical Co Ltd
KOSDAQ:086450

Watchlist Manager
Dongkook Pharmaceutical Co Ltd
KOSDAQ:086450
Watchlist
Price: 17 520 KRW 7.03%
Market Cap: 770.2B KRW
Have any thoughts about
Dongkook Pharmaceutical Co Ltd?
Write Note

Dongkook Pharmaceutical Co Ltd
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Dongkook Pharmaceutical Co Ltd
Depreciation & Amortization Peer Comparison

Comparables:
000100
326030
128940
S
000250
C
068760

Competitive Depreciation & Amortization Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
D
Dongkook Pharmaceutical Co Ltd
KOSDAQ:086450
Depreciation & Amortization
â‚©24.4B
CAGR 3-Years
16%
CAGR 5-Years
17%
CAGR 10-Years
19%
Yuhan Corp
KRX:000100
Depreciation & Amortization
â‚©53.7B
CAGR 3-Years
-2%
CAGR 5-Years
-1%
CAGR 10-Years
9%
SK Biopharmaceuticals Co Ltd
KRX:326030
Depreciation & Amortization
â‚©15.3B
CAGR 3-Years
12%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
Depreciation & Amortization
â‚©97.7B
CAGR 3-Years
9%
CAGR 5-Years
14%
CAGR 10-Years
14%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Depreciation & Amortization
â‚©8.5B
CAGR 3-Years
8%
CAGR 5-Years
6%
CAGR 10-Years
8%
C
Celltrion Pharm Inc
KOSDAQ:068760
Depreciation & Amortization
â‚©20.6B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
30%

See Also

What is Dongkook Pharmaceutical Co Ltd's Depreciation & Amortization?
Depreciation & Amortization
24.4B KRW

Based on the financial report for Jun 30, 2024, Dongkook Pharmaceutical Co Ltd's Depreciation & Amortization amounts to 24.4B KRW.

What is Dongkook Pharmaceutical Co Ltd's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
19%

Over the last year, the Depreciation & Amortization growth was 21%. The average annual Depreciation & Amortization growth rates for Dongkook Pharmaceutical Co Ltd have been 16% over the past three years , 17% over the past five years , and 19% over the past ten years .

Back to Top